Evolocumab

依洛尤单抗

Report date: 2026/04/23 20:00:25

Base Information

Drug NameEvolocumab
Drug Alias NameEvolocumab (Genetical Recombination)依沃苏单抗Evolocumabum依伏库人单抗Repatha +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[23] 
Global Approved IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[6] 
Approved Indications in ChinaHomozygous familial hypercholesterolemiaAtherosclerosis
Original Approved Country/TerritoryEU
Original Approved Date2015/07/17
Country/TerritoryCzechiaBelgiumBulgaria +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstellas Pharma IncAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesLib Therapeutics LlcDuke UniversityAmgen Europe Bv +[11] 
Inactive CompaniesThe University Of British ColumbiaAmgen Astellas Biopharma KkAmgen Manufacturing Ltd +[4] 
Active IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[18] 
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes MellitusCoronary Artery Disease +[5] 

Other Information

ATC CodeC10AX13
Related LinksWikipediaDrugBankKEGG